Schnitzler syndrome: An under-diagnosed clinical entity

Haematologica

Volumn 98, Issue 10, 2013, Pages 1581-1585

  Jain, Tania ^a   Offord, Chetan P ^a   Kyle, Robert A ^a   Dingli, David ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; COLCHICINE; DAPSONE; DOXEPIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CHRONIC URTICARIA; DEATH; DYSPROTEINEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORBIDITY; OSTEOSCLEROSIS; PERIPHERAL NEUROPATHY; PROTEIN ELECTROPHORESIS; RETROSPECTIVE STUDY; SCHNITZLER SYNDROME; SKIN BIOPSY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHNITZLER SYNDROME; SURVIVAL RATE;

EID: 84884919635     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084830     Document Type: Article

References (18)

1. Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaloïde?). Cas cliniques. Journee Dermatologique d'Angers. 1972(46).
2. Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenström. Bull Soc Fr Dermatol Syphiligr. 1974;81:363.
3. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 2001;80(1): 37-44.
4. de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37 (3):137-48.
5. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010;5(38):20.
6. de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis. 2006;65(4):542-4.
7. Martinez-Taboada VM, Fontalba A, Blanco R, Fernández-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins, et al. Arthritis Rheum. 2005;52 (7):2226-7.
8. Gilson M, Abad S, Larroche C, Dhote R. Treatment of Schnitzler's syndrome with anakinra. Authors' reply. Clin Exp Rheumatol. 2007;25(6):931.
9. Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol. 2008;100(6):617-9.
10. Eisele L, Durig J, Huttmann A, Duhrsen U, Assert R, Bokhof B, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012; 91(2):243-8.
11. Bida JP, Kyle RA, Therneau TM, Melton III LJ, Plevak MF, Larson DR, et al. Disease associations with monoclonal gammopathy of undetermined significance: a populationbased study of 17,398 patients. Mayo Clin Proc. 2009;84(8):685-93.
12. Gaig P, Olona M, Munoz Lejarazu D, Caballero M, Dominguez F, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3): 214-20.
13. Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J Investig Allergol Clin Immunol. 2009;19 (Suppl 2):21-6.
14. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150(1):28-38.
15. Kyle R, Durie B, Rajkumar S, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-7.
16. Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Semin Neurol. 2003;23(2): 181-90.
17. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol. 2005;18(4):673-88.
18. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-30.